Meeting
2024 ASCO Genitourinary Cancers Symposium
Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.
Authors
Ana-Alicia Beltran-Bless
The Ottawa Hospital, Ottawa, ON, Canada
Ana-Alicia Beltran-Bless , Noa Shani Shrem , Sunita Ghosh , Camilla Tajzler , Lori Wood , Christian K. Kollmannsberger , Naveen S. Basappa , Jeffrey Graham , Nazanin Fallah-rad , Daniel Yick Chin Heng , Denis Soulieres , Aly-Khan A. Lalani , Rodney H. Breau , Antonio Finelli , Simon Tanguay , Bimal Bhindi , Georg A. Bjarnason , Frederic Pouliot , Christina M. Canil
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Cancer Disparities
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 367)
DOI
10.1200/JCO.2024.42.4_suppl.367
Abstract #
367
Poster Bd #
E13
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).
First Author: Connor Wells
Poster
2024 ASCO Genitourinary Cancers Symposium
Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
First Author: Regina Barragan-Carrillo
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Audreylie Lemelin
Poster
2021 ASCO Annual Meeting
Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
First Author: Chun Loo Gan